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ABSTRACT
Background: For gravely ill patients who have no treatment options and
who are ineligible for clinical trials, the US Food and Drug Administration
(FDA) established the Expanded Access Program (EAP). Motivated by
efforts to weaken FDA regulation and sold as providing greater access to
experimental drugs, the federal Right to Try Act (RTT) was passed in 2017.
It reduces FDA oversight by not requiring physicians to report safety data
and foregoes approval of protocols by local institutional review boards.
Methods: This study explored the views of 17 neuro-oncologists from
15 different academic medical centers with varying experience with EAP
and RTT using convenience sampling. We conducted semi-structured interviews and qualitative analysis to identify emerging themes.
Results: Most oncologists were confused between the two pathways, had
little familiarity with RTT, and had little knowledge about experimental
medicine available through either pathway. Oncologists reported a preference of enrolling patients in clinical trials over off-trial preapproval pathways
with scant data. As a result, oncologists revealed concerns over properly
evaluating risks for their patients.
Conclusion: Our findings suggest that neuro-oncologists need better
resources and clearer mechanisms at their institutions to help navigate EAP
and RTT in order to counsel patients interested in experimental medicine.
Expanded Access, Right to Try, FDA, ethics, neurooncology, Compassionate Use
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I.A. Non-trial preapproval access: Expanded Access, Compassionate Use
and Right to Try

For gravely ill patients who have no viable treatment options and who are ineligible to
participate in clinical trials, the US Food and Drug Administration (FDA) established
the Expanded Access Programs (EAPs) in 1987.1,2 There are three types of EAPs:
for single patients (also called ‘Compassionate Use’), intermediate size populations,
and treatment group populations. Single patient EAP requests can be made to the
FDA for emergency and non-emergent situations with different approval times and
mechanisms. In the context of a single patient EAP, unapproved products can be given
to patients at various stages of clinical development. From a single major cancer center,
over three-quarters of single patient EAP protocols were drugs being tested in phase 2
or 3 trials, but nearly 20 per cent were tested in phase 1 safety trials.3
Over the years, the FDA has streamlined the process to improve access to experimental cancer medicines outside of a clinical trial, in part by establishing Project
Facilitate. This project helps streamline the administrative elements of EAPs by providing a call service and helping physicians complete the application.4 Additional
improvements include requirement of a shorter, 2-page application form, which takes
physicians approximately 45 minutes to complete, and review by a single member of
the Institutional Review Board (IRB).5,6 However, companies are not obligated to
provide experimental drugs to patients. Furthermore, companies cannot profit from the
provision of drugs, but they may charge for manufacturing and other related costs. The
EAP regulations also stipulate reporting requirements to the agency, including adverse
events. This regulatory process has been relatively expedient with over 99 per cent
of requests being approved, with turnaround approval times between 8 and 26 days,
against a target turnaround of 30 days for non-emergency situations. The average time
to approval for non-emergent individual patient INDs is 4 days, and emergent IND
approval may be granted over the phone within hours.7,8 The FDA has also put forward
education to physicians, patients, and sponsors.9
1 The Food and Drug Administration, CFR—Code of Federal Regulations Title 21, http://www.accessdata.fda.
gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.9
(accessed Oct. 19, 2021).
2 The Food and Drug Administration, Expanded Access Program Report https://www.fda.gov/me
dia/119971/download (accessed July 1, 2021).
3 Feit NZ, Goldman DA, Smith E, Deighan J, Iasonos A, Zivanovic O, Hyman DM. Use of the US Food and
Drug Administration Expanded Access Program, 5 Jama Oncol., 4, 570–572 (2019).
4 The Food and Drug Administration, Project Facilitate, https://www.fda.gov/about-fda/oncology-center-e
xcellence/project-facilitate (accessed July 1, 2021).
5 The Gao Report, Investigational New Drugs: FDA Has Taken Steps to Improve the Expanded Access Program
but Should Further Clarify How Adverse Events Data Are Used, https://www.gao.gov/assets/gao-17-564.pdf
(accessed July 1, 2021).
6 The Food and Drug Administration, How to Submit Request Forms, https://www.fda.gov/news-events/expa
nded-access/expanded-access-how-submit-request-forms (accessed July 1, 2021).
7 Jarow JP, Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research
Over a 10-Year Period, 50 Ther. Innov. Regul. Sci., 6, 705–709 (2016).
8 Jarow JP, Ten-year experience for the Center for Drug Evaluation and Research, Part 2: FDA’s Role in Ensuring
Patient Safety, 51 Ther. Innov. Regul. Sci., 2, 246–9 (2017).
9 Regan Udall Foundation, Expanded Access Navigator, https://navigator.reaganudall.org/ (accessed July 1,
2021).
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10 Fernandez-Lynch H and Bateman-House A. Facilitating both Evidence and Access: Improving FDA’s Accelerated
Approval and Expanded Access Pathways: Health Policy Portal. 48 J.L. Med. Ethics, 365 (2020).
11 Zach S, An Examination of the Right to Try Act of 2017 and Industry’s Potential Path Moving Forward, 92 S.
Cal. Law Rev., 331–410 (2019).
12 United States v. Rutherford, 442 U.S. 544 (1979).
13 Allison J Goodman, Abigail Alliance v Von Eschenbach: Restricting Access to Potentially Lifesaving Drugs since
2007, 25 J. Contemp. Hist. Law Policy, 1 (2008).
14 Begg C.B., Kum K.M., Neaton J.D., Right to Try Laws. 5 Clin. Trials, 11, 519–520 (2014).
15 Goldwater Institute, What Is Right to Try? http://righttotry.org/about-right-to-try/ (accessed July 1, 2021).
16 Goldwater Institute, Dr Ebrahim Delpassand’s Official Response to Congressman Pallone and Activist McFayden,
http://righttotry.org/dr-ebrahim-delpassands-official-response-to-congressman-pallone-and-activistmcfayden/, (accessed Mar. 15, 2022).
17 Id. at 15.
18 Chapman CR, Eckman J, Bateman-House AS. Oversight of Right-to-Try and Expanded Access Requests for OffTrial Access to Investigational Drugs, 42 Ethics Hum. Res., 1, 2–13 (2020).
19 Kearns L and Bateman-House A, Who Stands to Benefit? Right to Try Law Provisions and Implications, 51 Ther.
Innov. Reg. Sci., 2, 170–176 (2017).
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Despite these largely positive developments, there have been calls for greater reform
of FDA pathways, including making Project Facilitate a permanently funded program,
addressing barriers for small companies considering offering EAP, and broadening
clinical trial eligibility whereby EAP is authorized only when trial participation is
infeasible.10
Gaining non-trial preapproval access from the FDA resulted in the modern form of
EAP. In the 1980s, the HIV/AIDS epidemic prompted the FDA to make significant
changes to improve patient access to drugs outside of clinical trials and to reduce the
time to final FDA authorization. The agency applied an informal standard to individual
requests for unapproved drugs until the FDA Modernization Act of 1997 codified what
is now known as the Expanded Access Program.11 More recent challenges have sought
to provide investigational drugs to terminally ill patients. In the 2000s the Abigail
Alliance case involved constitutional claims, and an en banc court ruled that ‘FDA
regulation of post-phase I drugs [was] entirely consistent with [the United States’]
historical tradition of prohibiting the sale of unsafe drugs’.12,13 And a decade ago US
Senators Brownback and Inhofe sponsored a bill entitled the ‘Access, Compassion, Care
and Ethics for Seriously Ill Patients Act’. This bill also sought to permit marketing of
drugs after phase I testing. That bill never made it through committee and as a result
never came up for a vote.14
One federal law did, however, and now the Expanded Access Program is not the
only pathway to experimental drugs outside of a clinical trial. Given similar concerns
of government overregulation and denial of patient access to experimental medicine,
in 2014 the Goldwater Institute, among other think-tanks, put forth policy supporting
a patient’s ‘Right-to-Try’ experimental medicine, with a testimonial from an oncologist
treating terminally ill patients serving as a centerpiece rationale for the policy.15,16 This
concept was part of a movement to ensure quicker access to experimental drugs while
limiting governmental powers. Goldwater also drafted model Right-to-Try (RTT)
legislation that was enacted in 41 states.17 Generally, state RTT laws permit physicians
to request access to investigational drugs on behalf of patients in the absence of FDA
and IRB oversight.18 State laws generally specify that physicians cannot be disciplined
for recommending or prescribing investigational medication and that patients can try
these products after obtaining informed consent.19 Heterogeneity among state laws
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20 Id. at 18.
21 Barlas S, ‘Right to Try’ Legislation Moving Through Congress but Drug Companies and Some Patient Groups Want
Changes, 45 Mod. Healthc., 42, 10. (2015).
22 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 https://
www.congress.gov/bill/115th-congress/senate-bill/204/text (accessed July 1, 2021).
23 Id. at 18, 20.
24 Hamblin J. The Disingenuousness of ‘Right to Try’. The Atlantic, June 2, 2018, at 1.
25 Scott CT, A ‘Right to Try’ But at What Cost? https://blogs.bcm.edu/tag/right-to-try/ (accessed July 1, 2021).
26 Master, Z., Tilburt, J.C., Physicians’ Ethical and Professional Obligations about Right-to-Try Amidst a Pandemic.
20 Am. J. Bioeth. 9, 26–28 (2020).
27 Joffe S and Lynch HF, Federal Right-to-Try Legislation—Threatening the FDA’s Public Health Mission. 378 N.
Engl. J. Med., 8, 695–697 (2018).
28 Bateman-House A, Robertson CT. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward, 178 Jama Intern. Med. 3, 321–322 (2018).
29 Zettler PJ, Greely HT, The Strange Allure of State ‘Right-to-Try’ Laws, 174 Jama Intern. Med. 12, 1885–1886
(2014).
30 Id. at 18, 20, 23.
31 Id. at 26.
32 Id. at 27.
33 Id. at 28.
34 Gabay M., A Rapid Review of Right to Try, 53 Hosp. Pharm. 4, 234–235 (2018).
35 Bateman-House, Kimberly L, Redman B, Right-to-Try Laws: Hope, Hype and Unintended Consequences, Ann.
Intern. Med. 163, 796–797 (2015).
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surround patient eligibility of the ‘terminally ill’ definition and provisions of informed
consent. Some state RTT laws permit insurers to deny treatment coverage for harms
resulting from the experimental product or make patient who try experimental products ineligible for hospice care.20 Despite the high numbers of state level laws, there has
been little uptake of RTT by physicians and their patients.21
In 2017, former President Trump signed into law the federal RTT Act.22 Both federal
and state RTT laws have come under broad criticism by ethicists, scientists, clinicians,
and some patient advocacy organizations and policymakers.23–29 Criticism primarily
focuses on the increased health and safety risks of patients with many drugs being
sought after initial phase 1 safety testing, the lack of regulatory and ethics oversight,
few details surrounding the provision of informed consent, limited monitoring and
reporting requirements, and the redundancy of the law as EAP already granted patients
access to investigational drugs, with near 100 per cent approval by the FDA and rapid
turnaround.30–33 In addition, two-thirds of early phase drugs fail in later phases of
testing, potentially exposing patients to risk and side effects. Despite the legislative
focus on the FDA’s shortcomings, it is important to note that decision to provide drugs
under RTT, as it is with EAP, is at the discretion of the drug companies. Opponents
suggest that RTT does not really grant access to experimental medicines, but rather
only guarantees a ‘right to ask’ the drug maker. The manufacturer may deny access, and
many advertise that they will not honor RTT requests, for fear that adverse effects may
interfere with the success of their application to the FDA.34
In summary, Bateman-House et al. underscore the legal fallout from RTT: ‘(RTT)
ignores both the complexity of deciding when access makes sense for desperate patients
and the reality that resources are needed to make access possible. Choice without
obligation leaves patients where they were before the laws were enacted: begging
companies for compassion.’35
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36 Lo B, A Parallel Universe of Clinical Trials, 379 Nejm., 101–103 (2018).
37 Smith C, Stout J, Adjei AA, Buckner J, Wentworth M, Tilburt J, Master Z. ‘I think it’s been met with a shrug:’
Oncologists’ Views Toward and Experiences with Right-to-Try, J. Natl. Cancer Inst., 1–7 (2020).
38 Id. at 26, 31.
39 Fountzilas E, Said R, Tsimberidou AM. Expanded Access to Investigational Drugs: Balancing Patient Safety with
Potential Therapeutic Benefits. 27 Expert Opin. Investig. Drugs, 2, 155–162 (2018).
40 Morrison C. Critics Say ‘Right-to-Try’ Wrong for Patients, 36 Nat. Biotech., 4, 294–296 (2018).
41 Bunnik EM, Aarts N and van de Vathort S. Views and Experiences of Physicians in Expanded Access to
Investigational Drugs, 39 Clin. Ther., 8, 96 (2017).
42 Bunnik EM, Aarts N. What Do Patients with Unmet Medical Needs Want? A Qualitative Study of Patients’ Views
and Experiences with Expanded Access to Unapproved, Investigational Treatments in the Netherlands. 20 BMC
Med. Ethics., 1, 80 (2019).
43 Id. at 37.
44 Moerdler S, Zhang L, Gerasimov E, Physician Perspectives on Compassionate Use in Pediatric Oncology, 66 Ped.
Blood Cancer, 6, 3 (2019).
45 Zettler ME, Jeune-Smith Y, Feinberg BA, Phillips EG, JD Pharm, and Gajra A. Expanded Access and Right to
Try Requests: The Community Oncologists’ Experience, JCO Oncol. Pract. (2021).
46 Chapman CR, Belli HM, Leach D, Shah LD, Bateman-House A. A Survey of Pediatric Hematologists/
Oncologists’ Perspectives on Single Patient Expanded Access and Right to Try, 5 Med Access. 1–10 (2021).
47 Id. at 27, 32.
48 McKee AE, Markon AO, Kirk MC, Lurie P, How Often are Drugs Made Available Under the Food and Drug
Administration’s Expanded Access Process Approved? 57 Clin. Pharm., 136–142 (2017).
49 Okie S, Access Before Approval—A Right to Take Experimental Drugs? 355 N. Engl. J. Med., 5, 437–440
(2006).
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I.B. Two Competing Federal Pathways

At present, patients, physicians, and companies are faced with two competing federal
pathways, and the publicity surrounding RTT may mean physicians receive more
requests for unapproved drugs outside of clinical trials.36 The existence of parallel
pathways could result in patient and provider confusion, a need for greater resources,
and potential distress for both patients and physicians. Patients and clinicians may
be confused about what the RTT law means, given the lack of a positive right obligating a drug company to provide experimental medications to patients. One study
of experienced oncologists’ attitudes towards off-trial medication showed that several
physicians misunderstood and reported that the federal RTT legislation does offer a
right for patients to access experimental drugs.37 Clinicians might also have to decide
whether patients are truly ineligible from enrolling in clinical trials and whether they
are siphoning resources from randomized trials.38 While EAP is not without its own
shortcomings, including issues of equitable access, most scholars argue that RTT
deprives patients of necessary oversight that can reduce harm, and prevents the FDA
from using adverse event reporting during the drug approval process.39 ,40
Given the importance of enhancing clinical research and providing out-of-option
patients access to experimental drugs on the basis of compassion, little is known about
physician and patient attitudes regarding these pathways. At present, only a handful of
studies capture physicians’ experiences with EAP and RTT, and a couple of these studies were performed in specific settings.41–47 To better understand the views of clinical
oncologists, we aimed to explore the attitudes of experienced clinical neuro-oncologists
who treat patients with brain tumors towards EAP and RTT. Oncology is one the
most prolific areas where physicians obtain experimental products through EAP.48 This
demand is especially acute in neuro-oncology, where few effective treatments exist, and
many patients face end-of-life decisions.49 In this study, we interviewed 16 oncologists

6

•

Prescribing unproven cancer drugs

II. METHODS

We undertook a qualitative approach as it permits a deeper understanding of the
knowledge, ideas, beliefs, and motivations that shape the attitudes of clinical trialists
since at the time of commencing the study, only one paper had been published on
physicians’ attitudes and experiences on RTT. Our literature review and preliminary
research determined a strong rationale for picking cancer as a therapeutic area. The
history of FDA challenges include access to unapproved cancer drugs (Laetrile, 1970s;
Abigale Alliance, 2000s). And, FDA data show over a third of EAP requests are cancer
related. Lastly, we could find no study examining RTT and EAP in the oncology
context.50
II.A. Recruitment

We used purposive sampling to identify neuro-oncologists who have experience with
expanded access and/or RTT. Identification of experience with expanded access
and/or RTT came from searches in ClinicalTrials.gov along with networking with
other neuro-oncologists in the field. Searches in ClinicalTrials.gov identified studies
and investigators listing participation in EAP. There were no restrictions on age, sex, or
ethnicity, but all physicians had to currently be practicing in the United States.
We identified neuro-oncologists who participated as part of the multi-site GLIOGENE study as well as using ClinicalTrials.gov to recruit neuro-oncologists with EAP
and/or RTT experience. From the GLIOGENE study, 2 neuro-oncologists participated in our interviews. From ClinicalTrials.gov, we contacted 27 oncologists who
participated in an Expanded Access Protocol for glioblastoma multiforme. After we
contacted these 27 oncologists by email, 7 agreed to participate. We asked these
initial participants to recommend additional possible participants, which resulted in
recruitment of an additional 8 participants, for a total sample of 17 oncologists.
II.B. Interviews and Interview Guide

We developed a semi-structured interview guide based on findings from previous
studies and modified it inductively after the first five interviews.51,52 The interview
guide contains questions in 3 domains—knowledge, familiarity with EAP and RTT,
and patient-physician conversations about unapproved drugs—totaling 14 questions
(see Supplemental Information).
Informed consent was obtained verbally prior to beginning interviews. Interviews
were conducted either by Zoom© or telephone and ranged from 43 to 63 minutes
(averaging 53 minutes). Interviews were conducted by at least two members of the
research team. Fourteen of these interviews were conducted by Haley Manley (HJM),
eleven by Christopher Scott (CTS), six by Bryan Sisk (BS), and four by Zubin Master
50 Brower V. Food and Drug Administration Responds to Pressure for Expanded Drug Access, 106 J. Natl. Cancer
Inst. 6, 1–9 (2014).
51 Id. at 37, 43.
52 Id. at 41, 42.
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who predominantly cared for patients with brain tumors and 1 radiation oncologist
all of whom had experience with pursuing experimental drugs via either EAPs and/or
RTT pathways.
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II.C. Codebook Development and Qualitative Analysis

Initial codebook development began with all members of the research team discussing
two interviews identified as robust in terms of knowledge and experience with EAP
and RTT. All team members added memos to transcripts individually, then collectively
developed an initial codebook outlining possible themes. Two researchers (CTS and
HJM) further analyzed additional transcripts to finalize the codebook which was
then presented and discussed with all four team members. Qualitative analysis was
performed using a modified grounded theory approach with constant comparison
analysis.53,54 Transcripts were then individually coded and emergent themes were
organized using Dedoose 8.3.47. A basic descriptive analysis was undertaken, followed
by a comparison of codes within and between participants. Two rounds of abstractions
were carried out to identify themes. Areas of confusion or disagreement were discussed
and clarified through consensus. The full team reviewed and approved the final set of
themes, definitions, and supporting quotes.
III. RESULTS

We interviewed 17 clinical researchers who had participated in oncology trials, represented by 15 different academic institutions from 10 different states with 8 females and
9 males. Sixteen oncologists focused on neurologic tumors, and one oncologist focused
on neuroendocrine tumors. Nearly all participants were investigators on clinical trials
for glioblastoma, and 4 participants were co-investigators on a multisite trial that
mentioned EAP as a treatment option in their publications. Fifteen of 17 participants
had previously completed at least one EAP protocol. Nearly half of our participants
had patients who requested drugs through RTT, but only 3 had administered the
experimental agent to patients through RTT.
Below, we describe 2 interrelated themes that influenced participants’ views on EAP
and RTT (summarized in Table 1).
III.A. Misconceptions and Confusion about EAP and RTT

Many physicians described having difficulty in distinguishing between RTT and EAP
or demonstrated misconceptions in their responses. A physician with knowledge of
both pathways spoke about his colleagues generally: ‘I don’t think a lot of people
understand the difference between expanded access and Right-To-Try’ [Participant 1].
The confusion resulted in conflation with the different features between EAP and RTT
including structure, intent, and processes of these pathways. In response to our question
‘Have you provided a drug through Right-to-Try?’ one clinician erroneously replied, ‘I
think most compassionate use is under that category’ [Participant 2]. Another drew a
rough equivalence between the two despite the absence of FDA oversight for RTT: ‘I
guess the way I try to think about Right-to-Try is like compassionate use. If there’s some
53 Straus A, Corbin J. Basics of Qualitative Research: Grounded Theory Procedures and
Technique (1990).
54 Charmaz K. Constructing Grounded Theory (2014).
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(ZM). Interviews were audio recorded and professionally transcribed. This study was
approved by Baylor College of Medicine’s IRB (H-46177).
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Theme/subtheme

Explanation

Theme 1. Misconceptions and confusion about EAP and RTT
Physicians misconstrued definitions, processes,
and provisions surrounding FDA’s EAPs and the
federal RTT law
Theme 2. Physicians’ opinions, preferences, and experiences with EAP and RTT
Logistical barriers
Physician experiences with EAP and RTT
influenced their attitudes around administrative
burdens and logistical barriers mostly
surrounding IRB review and less so around FDA
oversight
EAP and RTT versus clinical trials
Physicians largely preferred to involve patients
seeking experimental medicine in clinical trials
over non-trial pathways
Case-by-case decisions
Physicians describe those situations warranting
preapproval access need to be determined on a
case-by-cases basis taking into consideration the
clinical circumstances of each patient
Primacy of the patient’s values
Physicians respecting patient autonomy and
expressing the need for patients to make the final
decision on whether to pursue experimental
medicine
Physicians’ motivations for
The differences of opinions among physicians
pursuing EAP or RTT
for when it may be appropriate to use or not to
use either expanded access or RTT pathways
When physicians disagree with
Some physicians accept the use of unproven
patients’ desires or preferences
medicine for patients when it is not harmful to
the patient or their treatment, but if the
unproven medicine could cause harm, physicians
would warn patients

sort of biologic or scientific rationale outside of any FDA authorization, and then if it is
deemed safe by the physician, then you can prescribe that’ [Participant 3]. Another
physician defined RTT as ‘where basically you can try repurposing drugs’ [Participant 4]. This statement indicated that the physician confused off-label prescriptions
with drugs available through RTT. A minority of physicians demonstrated a nuanced
understanding about the differences between EAP and RTT. For example, one neurooncologist said ‘ . . . if you read the law in more detail, it’s not really right to try. It’s more
right to request. Right to try implies that the person would decide I want to try this and
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Table 1. Summary of themes generated from qualitative interviews of neurooncologists
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III.B. Physicians’ Opinions, Preferences, and Experiences with EAP and RTT

Our second major theme focused on physician’s opinions, preferences, and experiences
with off-trial pathways and were broken down into 6 subthemes: Logistical Barriers,
EAP and RTT versus clinical trials, case-by-case decisions, primacy of the patient’s
values, physicians’ motivations for pursuing EAP or RTT, and when physicians disagree
with patients’ desires or preferences.
Logistical Barriers
Physicians’ past experiences with EAP and RTT seemed to influence their approaches
and strategies for obtaining experimental medicines for patients. Though most physicians were neutral or positive about working with the FDA, some participants believed
that overly rigid FDA regulations harmed some patients. This inflexibility drove one
investigator to pursue RTT: ‘[The FDA] stated this might not be safe for the patient and
I asked them has anyone complained? Taking this chance, I think it’s very reasonable.
In any kind of cancer therapy, you have this kind of toxicity. They [just] have to go
by those guidelines and those rules that are given to them’ [Participant 5]. Another
participant perceived the changing requirements for submission of EAP requests were
cumbersome, took precious time from clinical practice, and were costly: ‘While I
understand the good intentions of all these processes, it just seems like every year there’s
more and more added on . . . some of it is mandated at the federal level. And the thing
I worry about more at the broader level is a lot of all of this really adds usually to the
costs’ [Participant 6].
When asked about specific barriers encountered in applying for EAP approval,
participants mentioned deadlines and time delays imposed by local IRBs. For example,
some physicians would forgo EAP if a local IRB was perceived to be a barrier to the efficient acquisition of a medication, regardless of how smoothly the interaction with the
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I’m going to get it. Period. That’s not actually what’s written in the law. It really should
be a right to request.’[Participant 6].
Physicians also described how some patients held misperceptions about EAP and
RTT. For instance, one physician spoke of how patients have trouble understanding
the development of clinical trials as it relates to EAP/RTT, I do spend a lot of time
explaining the difference, phase one clinical trials are evaluating whether something’s
toxic to humans and phase two clinical trials, it it’s effective and not toxic. Then phase
three, if it’s effective against that particular tumor and that’s how we get to standard of
care. People don’t seem to have any real understanding of this. They’ve even developed
groups now who say, ‘Nobody should have to settle for standard of care’ [Participant
10].
One senior investigator attributed the rise of RTT to a general misperception by
other patients, advocates, and physicians that the FDA was the primary barrier to access,
“We’ve dealt a lot with Right-to-Try, and I think the people who are behind it don’t
really understand that the FDA is not really the barrier here” [Participant 1]. Another
physician stated, “My understanding [is that our] patients could come to us and say,
‘We have the right to try this drug.’ But that still doesn’t answer the question how we
get the institutional support to give this drug and to do the oversight safety monitoring
and things like that” [Participant 2].
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EAP and RTT Versus Clinical Trials
All participants suggested that they preferred other means of providing experimental
drugs to patients including clinical trials and as off-label over EAP and RTT: “We
basically always go clinical trial. If we can’t do clinical trial, then we’ll see if there’s
anything out there that makes sense to use it as an EAP, and if not, one of the things
that we do now for every single patient is molecular [targeting] A lot of institutions
have their own home-cooked molecular analysis.” [Participant 1]. One reason for
this preference was administrative: “For me, the biggest hurdle when it comes to
expanded access is the amount of administrative work it actually takes . . . you have to
write a five-page protocol and a consent form and then this will be reviewed by our
pediatric scientific committee; then it will be reviewed by our cancer center, and then
it has to get IRB approval in the midst of us getting FDA approval” [Participant 7].
Another reason was the desire to advance scientific knowledge, which clinical trials
accomplished. Physicians also described how clinical trials provided reassurance about
the biological plausibility of the treatment: “[A] lot of people have thought about this
trial, and if they didn’t think it had any [biological plausibility], then most likely they
will not offer it” [Participant 7]. In this way, the clinical trial provided the physician
with more confidence in the decision to pursue unproven therapies. Others stated that
they could not justify EAP or RTT when better alternatives exist: “If you’re talking
to somebody who is at their very first recurrence of the disease and we’ve got other
clinical trials available, and we’ve got other standard treatments available, then it’s like
are we really going to go through the whole process of getting EAP for something which
we really don’t know if it works when we’ve got other decent options on the table?”
[Participant 8].

Case-by-Case Decisions
Many physicians expressed that decisions to pursue EAP or RTT needed to be made
on a case-by-case basis, where clinical circumstances dictate the final decision. One
oncologist said, “We look for an Achilles heel that could be an actionable mutation.
If that actionable mutation has a drug that is commercially available, of course we’ll
think of that. If it is an actionable mutation for which there’s investigational drugs,
not commercially available, the only way to get it is an EAP, we would talk about it
that way” [Participant 1]. However, another clinician said that a case-by-case basis is
not how these decisions should be made: “My worry is that single use on a case-bycase basis, it doesn’t fulfill that general goal of learning from each patient case” [Participant 9]. Nonetheless, the participant later stated certain circumstances that might
justify experimental treatments for specific cases: “I think we as oncologists . . . want
to do what’s best for every single patient themselves, and there are sometimes very
specific circumstances that might justify approaching otherwise investigational medical
products in a way if they aren’t a trial candidate, that might still benefit a patient”
[Participant 9].
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FDA might go. When institutions had staff and infrastructure dedicated to supporting
EAP, participants seemed to have more positive assessments of these pathways.
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Physician Motivations for Pursuing EAP or RTT
A few physicians expressed strong preferences for EAP rather than RTT even if they
misunderstood the differences about them: “Right-to-Try is an abomination, it should
never have been written. Nobody in the health care field wanted it written, not the FDA,
not the [American Cancer Society], not anybody. It means that you’re getting access to
a drug from a company–not a physician–without the purview of the FDA. Makes no
sense . . . We will never do right-to-try, and most physicians will not do right-to-try”
[Participant 1]. However, most physicians did not make major distinctions between
using either EAP or RTT. Instead, most described their approaches, in general, to
accessing unproven medications for patients.
Clinicians described several motivations for pursuing EAP or RTT. Many discussed
the importance of supporting the patient’s hopes, particularly hope for survival: “I
think hope is very important. Earlier on in my career I used to be very much of the
mindset that you don’t give false hope. You shouldn’t try to give false hope. But over
the years what I’ve seen is that for a lot of patients, hope is what keeps them going.
They get very depressed when they don’t have hope” [Participant 11]. Other times,
participants described pressure to offer treatments and feelings of guilt if they did not
offer treatments: “The husband said to me, ‘Oh, so now we’re just going to be left out
in cold, huh? There’s nothing else to do.’ And that, it was just jarring emotionally to
me, that I felt like I was abandoning these people that I really liked” [Participant 3].
Physicians also described a personal sense of urgency to do something—anything—
for their patients: “In most cases it’s desperation . . . You’re just watching this tumor
grow. People are desperate, and you want to help. You want to do anything you can to
help.” In neuro-oncology particularly, this desperation is exacerbated by a lack of proven
treatment options: “This is neuro-oncology. We have exactly two treatments that have
been approved by the FDA” [Participant 4].
Beyond these patient-focused motivations, some physicians described feeling a thrill
from identifying a treatment for patients that others might have missed: ‘I mean, there’s
so much excitement to [finding a novel treatment] . . . I, selfishly, have some of that
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Primacy of the Patient’s Values
Although physicians themselves may have their own preferences for treatment, most
expressed that the patient can decline an unproven drug, and physicians can decline
to administer drugs if they are not in the patients’ interest. However, physicians also
described how patients might struggle to make logical decisions given their desperate
conditions: “I would say despite those conversations, particularly in the world of brain
tumor patients, that if you have a targeted drug and the tumor has the target 100 per cent
of the time, despite that conversation, they’re going to say, ‘Give me the drug.’ I’ve never
had a situation where anybody turns it down, even when we talk about the risk-benefit”
[Participant 10]. One physician described how he typically recommends palliative care
when he feels experimental drugs or interventions could lead to morbidity, toxicity, and
earlier death. However, he recounted one experience where he complied with a patient
request for additional treatment, even though he did not believe the treatment would
be effective. “We tried radiation and the patient died three days after completing the
radiation. I understand how the emotion of that, of my relationship with those people,
is what led me to make the wrong decision” [Participant 3].
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When Physicians Disagree with Patients Desires or Preferences
Despite these motivations to offer unproven medications, several physicians described
situations where they disagreed with the patient’s treatment preference. When this
disagreement related to minor, non-harmful interventions, the physicians tended to
accommodate the patient’s preference: “If they want to take CBD oil because their
friends, coworkers, aunt, took it and the breast cancer disappeared. I’ll say, ‘Great.
There’s no problem if you do that but I still think we should explore these other
conventional therapies.’ If the choice seemed harmful, however, several physicians
described refusing the patient’s request: “If I’m really not convinced it’s a good idea, I
definitely say no. If I really think this is not providing, or even doesn’t have the potential
to provide benefit . . . if I’m really not convinced, then I’m not offering this” [Participant
11]. This refusal could have implications on the patient’s coping and hope: “You don’t
want to be Debbie Downer, unfortunately, that’s sometimes how they will see you, as
the one who is throwing sand in their face, and that you just aren’t as hopeful as they
seem to be in their fantasy. But you need to explain that there is a downside to all of this
mad pursuit for the ephemeral cure” [Participant 12].
IV. DISCUSSION

Perhaps the most significant finding from our study showed that many oncologists
were not fully aware of the differences between EAPs and RTT. The confusion around
terminology among physicians and their understandings of the provisional differences
between off-trial pathways has been well-documented. In one study conducted primarily at a single major medical center with three sites across the U.S., researchers
observed confusion among clinical oncologists surrounding what the federal RTT law
truly meant in terms of patients’ right to accessing investigational drugs, the role of drug
companies, IRB involvement, and the eligibility of drugs.55 In one survey, confusion
between EAP and RTT included conflation over structure, intent, and the procedural
differences among the two pathways.56 In this survey study of 238 physicians, only
27 per cent were able to identify the main differences between EAP and RTT.57 In
another study surveying pediatric oncologists, researchers found that acquiring drugs
off-label was sometimes imprecisely considered EAP,58 which was seen by one physician in our study. This disconnect was clearly apparent in our analysis of transcripts.
Instances of conflation and confusion between EAP and RTT abound, with some
55
56
57
58

Id. at 37, 43, 51.
Id. at 45.
Id. at 45, 56.
Id. at 46.
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excitement. I feel like I’m cracking a code or something, or that it’s my ingenuity
and drive that’s going to bring those patients something, that’s going to help them,
that otherwise would not have happened.’ [Participant 3]. Even when interventions
failed to benefit the patients, physicians seldom found that patients were angry or upset
about pursuing unproven agents: ‘This is a constant question we are asking ourselves,
“Do they really understand?” I’ve never been surprised in the end, that then families
were mad at us. It’s always more we have a conversation like, “At least we tried.”’
[Participant 7].
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investigators identified as participating in trials listing EAP as an option on ClinicalTrials.gov having a limited understanding of that longstanding pathway of preapproval
access. The lack of clarity around terminology among preapproval pathways and offlabel prescribing is likely to contribute to confusion and possibly hinders patients’
access to treatment.59 Patients fortunate enough to have doctors familiar with the process and its associated terms are more likely to gain access to experimental treatments
than those whose doctors are unaware of the options or not as adept at navigating
preapproval pathways.60 .
These results show a pressing need to better inform oncologists about preapproval
pathways, including the differences among them and how best to navigate them. In a
qualitative interview study where researchers informed oncologists about differences
between EAP and RTT, several oncologists expressed a desire for greater education and
resources to navigate preapproval pathways.61 There are several notable educational
guides on the market including information produced by the American Society of
Clinical Oncology and the Expanded Access Navigator developed by the Reagan-Udall
Foundation for the FDA.62–65 Anecdotally, when we asked physicians about their
awareness of some of these resources, many reported not knowing about them, which
suggests that training programs for oncologists may be necessary in order to deliver
information and resources about EAPs and RTT. Master et al., go a step further to
posit that a natural extension of education would be to develop shared decision-making
tools for oncologists in order to foster better patient-physician conversations about
experimental cancer care in response to an individual patient’s situation, desires, and
available therapies.66
A second major finding in our study was the level of administrative burdens associated with EAP, which are consistent with other studies, and includes concerns over the
time and resources needed to secure the investigational product for patients and the
timeliness of FDA and IRB reviews.67–69 Expanded access places some administrative
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burdens on physicians that RTT does not70,71 .To approve a request through EAP, both
the FDA and IRB must authorize it. Once the physician has obtained approval from
the drug company, they must then obtain local IRB approval prior to administering the
drug, or else certify to the FDA that they meet conditions for a waiver of prospective
IRB review.72 The IRB review can be a time-consuming process, especially since these
submissions are often evaluated by people who might not be familiar with EAPs. One
study evaluating IRB approval time at a Veteran Affairs Medical Center found that total
review times ranged from 16 to 631 calendar days, with the median time for full board
review being the longest (131 days).73 This administrative delay affects physicians’
decisions as to whether or not to use EAP as some in our study suggested they would
forgo EAP if a local IRB was perceived to be a barrier to the efficient acquisition of
experimental medication. In several cases our participants mentioned the IRB as a
source of delay, with one respondent going so far to say his institution would not use
EAP because of the local administrative burden. On the other hand, one interviewee
praised her IRB in its knowledge of the fast-track features of EAP. Institutional-level
deficiencies are supported by the literature: the authors in one study suggest IRBs are
not a good fit for reviewing preapproval access requests; IRBs exhibit lack of uniformity
of terms and policies, especially for single patient expanded access.74 One rather
simple step forward would be a preapproval access training module offered to research
institutions through an organization such as Public Responsibility in Medicine and
Research (PRIM&R). Recently, several efforts have been undertaken to promote the
awareness of the EAP program and streamline the IRB process. For instance, a physician
submitting the new form can request that a single IRB member (the chairperson or
delegate) review the application, for the purpose of expediting the process.75
While EAP application processes were once much longer and required more administrative steps, the FDA has reduced those thereby shortening timelines. The FDA
has managed to streamline the process through Project Facilitate, to help oncologists
request investigational cancer treatments for patients who are not eligible for a clinical
trial or who have exhausted currently approved treatment options.76 Prior to 2016,
filing for a single patient EAP investigational new drug (IND) application required the
same form as manufacturers had to complete for when filing an IND for a clinical trial.77
In response to concerns of administrative burdens, the FDA developed a simplified twopage form (Form FDA 3926) which contains 11 instead of the 26 elements necessary
for clinical trials.78 Combining these attributes by the FDA along with other aspects
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to expedite the administrative processes outlined in Project Facilitate ie a telephone
service, and requiring only review by a single member of the IRB, it is unlikely that
the FDA itself is overly burdensome for most oncologists. Some of our participants
somewhat acknowledged this sentiment indicating that FDA authorization procedures
have improved. Given that oncologists in our cohort and from other studies really did
not know about process differences between EAP and RTT, and that some preferred
RTT when any administrative challenge was met, we wonder whether oncologists have
a general aversion to any additional administrative work.
Since many oncologists in our study and evidence from other research show confusion about the administrative process of EAP, they may confuse where the challenges
lie. Some oncologists in our study sought RTT as an alternative pathway to lower
administrative burden and gain access to experimental medications to their patients
faster. This suggests that education for oncologists needs to not only alert them to
definitions and differences in the provisions between preapproval pathways, but to
also provide insight into the value and reasons for why regulatory and ethics oversight
is necessary. Expressing to oncologists the value of having FDA review ie knowledge
into dosing and monitoring requirements, and IRB review of the ethics and informed
consent aspects may suggest to busy physicians that these administrative hurdles are
also necessary and serves to help them and their patients.
Proponents of RTT identify the FDA as the primary obstacle to accessing experimental therapies.79 In one case in our study, a perceived lack of transparency at the FDA
led to a wholesale adoption of RTT for a large cohort of terminally ill cancer patients.
In this case, the investigator was trying to procure a drug that was approved in the EU
but not yet by the FDA, and used his state-level RTT to source the drug. Eventually,
the drug in question was approved by the FDA, but long after the critical period of
access had passed for his patients. For all EAP categories, the FDA must determine
that the condition is serious or immediately life-threatening, that there are no similar or
satisfactory alternative therapies, and that access will not interfere with pivotal clinical
trials.80 Additionally, the FDA must determine the potential benefits outweigh the
risks.81 Nonetheless, although RTT supporters suggest that FDA decision making and
timing interferes with obtaining investigational drugs, studies such as those conducted
by Zettler et al. demonstrate that RTT is no more successful than EAP in gaining
access to unapproved drugs.82 What seems to be a significant barrier to obtaining
experimental therapies is the manufacturer rather than the FDA.
Seven oncologists in our study reported that the major obstacle in accessing experimental therapeutics was receiving approval from drug manufacturers. Major points
included in the difficulties in working with small biotechnology companies, time
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constraints in obtaining drugs for terminally ill patients, and the fact that provision of
drugs is discretionary. On this last point, manufacturers face a number of challenges;
they may worry that providing access outside of trials could deplete their limited
supplies of experimental products, make them liable for injuries to patients, and make
eventual FDA authorization less likely either because of adverse events that develop or
by deterring patients from enrolling in ongoing clinical trials.83 Even if the manufacturer is willing to provide an experimental drug for expanded access, the drug might be
too expensive and difficult to produce to allow for administration without participation
in a clinical trial.84
Further approaches for lessening the administrative burden between physicians,
the IRB, and the FDA have been suggested such as states partnering with the FDA
to fund multicenter IRBs that focus specifically on EAP requests.85 Others have that
an independent board of clinicians could determine whether a patient satisfies the
criteria for EAP to streamline the review process.86 One study evaluating oncologists’
experiences with RTT cited administrative personnel with expertise in these programs
as a crucial resource for reducing burdens and easing the clinical responsibility of physicians.87 Along with improved institutional knowledge, these solutions seem reasonable,
especially for the types of oncologists we interviewed for our study.
Although RTT requires approval from drug manufacturers as well, the other administrative hurdles of EAP formed the basis for why a few of our oncologists used RTT.
Albeit many of our oncologists suggested they did not pursue RTT because of its
procedural and legal ambiguity, some used it for its simplicity. Federal and state based
RTT laws generally lack provisions of FDA and ethics review and permit faster access
but at the possible costs to patients.88–90 While a vast majority (78.3 per cent) of 83
IRB members surveyed among different institutions indicated that it was important for
a designated member of the IRB to review single patient EAP requests, 16.8 per cent disagreed or strongly disagreed with such a statement.91 Interestingly, most respondents
supported a single designated reviewer policy but 65.1 per cent of participants reported
that full board review was necessary.92 These findings would suggest that the need for
further insight into the value of IRB review is required in order to assess its importance
and further streamline the process (if necessary). In addition, while respondents in
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V. CONCLUSIONS

This study represents an initial investigation evaluating misconceptions, barriers, and
experiences with EAP and RTT. Despite experience with obtaining experimental cancer drugs for their terminal patients, clinicians continue to express confusion over the
two pathways even three years after the passing of federal RTT legislation. Clinicians
considering RTT or EAP must balance patient and family hope, and importantly,
perceived, or real views about institutional, government or corporate impediments to
obtaining interventions when time for the patient is short. Additional work is needed
to understand how best to support physicians as they consider investigational therapies
for their patients. The results of our study also demonstrate that physicians need to be
better informed about the differences in off-trial pathways, especially the differences
between these pathways, clinical trials, and off-label medicine. These findings illustrate
the importance of clinicians’ experiences with experimental medicine and how preliminary experiences impact their future clinical care as well as opinions and motivation to
implement these therapies going forward.
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the study were quite familiar and responsive to EAP requests, other IRBs may be less
familiar with the EAPs.93,94
Although the FDA authorizes over 99 per cent of EAP requests and has created
Project Facilitate to further streamline processes, it remains unclear how many oncologists are deterred from fully completing the necessary administrative procedures of
filing an EAP IND or submitting IRB review because of actual or perceived administrative barriers. Several studies of provider attitudes suggest streamlining EAP processes as
opposed to abandoning them and thus further research is needed to better understand
administrative pain-points.95,96 Organizations such as academic health centers have
the infrastructure, intellectual capital, and high-quality care and research to accommodate units or groups within it to help facilitate EAP requests.97,98 It would be plausible
to add such groups within hospitals or medical centers that could facilitate procedural
steps for physicians, but this would be a resource intensive effort and unlikely to be
adopted by smaller institutions.
There are several limitations to our study worth noting. First is our small sample
size of 17 oncologists. Despite this small sample we did see saturation and our data
mirrors results in other published works.99 Additionally, physicians’ responses in our
study are self-reported and thus subject to recall bias. Furthermore, our focus on brain
cancers might not reflect the experiences of all other oncologists, or the perspectives of
non-oncology physicians and researchers. Also, all participants in this study were from
academic centers and were familiar with clinical trials. As such, these results might not
represent the experiences of oncologists at non-academic centers.
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